Progyny (NASDAQ:PGNY) Issues Quarterly Earnings Results

Progyny (NASDAQ:PGNY - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.36 by ($0.28), Zacks reports. The business had revenue of $298.43 million for the quarter, compared to analyst estimates of $277.31 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny updated its Q1 2025 guidance to 0.440-0.470 EPS and its FY 2025 guidance to 1.520-1.620 EPS.

Progyny Price Performance

Shares of NASDAQ:PGNY traded down $0.53 during midday trading on Monday, reaching $22.00. The company had a trading volume of 3,660,909 shares, compared to its average volume of 1,537,778. The stock's fifty day moving average price is $20.83 and its 200-day moving average price is $18.67. The stock has a market capitalization of $1.87 billion, a P/E ratio of 37.93, a PEG ratio of 2.39 and a beta of 1.34. Progyny has a one year low of $13.39 and a one year high of $38.98.

Insider Buying and Selling

In other Progyny news, CEO Peter Anevski bought 209,500 shares of the stock in a transaction on Monday, December 23rd. The stock was purchased at an average price of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now directly owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman David J. Schlanger bought 150,000 shares of the stock in a transaction on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares of the company's stock, valued at $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday. Truist Financial reiterated a "hold" rating and set a $19.00 price objective (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Barclays dropped their price objective on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $24.82.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.